KOS 862

Drug Profile

KOS 862

Alternative Names: Epothilone D; KOS-862; R 1492; Recombinant epothilone D

Latest Information Update: 01 Mar 2007

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 27 Feb 2007 Discontinued - Phase-II for Breast cancer in USA (IV-infusion)
  • 27 Feb 2007 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
  • 05 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the adverse events and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top